Free Health Updates
Skip to main content
Table of Contents
< All Topics
Print

Are There Shared Tips for Dosing Schedules of Cannabis in Dementia Care? 

Posted
Updated
ByMy Patient Advice
Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

When medical cannabis is considered for dementia-related symptoms such as agitation or sleep disturbance, dosing schedules become a key safety factor. Older adults are more sensitive to psychoactive effects and often take multiple medications, making titration a cautious process. Clinicians emphasise that while some families share anecdotal routines online, only specialists on the GMC register can prescribe cannabis-based medicinal products (CBPMs) legally under the Human Medicines Regulations 2012. 

According to NICE guidance NG144 and NHS England’s CBPM policy, dementia is not an approved indication for cannabis prescribing. However, in compassionate-use or research settings, specialists use structured dose-escalation plans to reduce side effects such as dizziness or confusion. 

Can medical cannabis be accessed legally for women’s health?

What The Evidence Suggests About Dosing 

Although no national dosing guideline exists for dementia, several studies have outlined safe titration methods. A 2022 Frontiers in Aging Neuroscience pilot in care-home residents used a THC:CBD ratio of 1:2, starting with 2.5 mg THC and 5 mg CBD twice daily, slowly increased over two weeks. Caregivers reported calmer behaviour and fewer agitation episodes without major side effects. 

Similarly, Israel’s 2024 cohort found that most older adults tolerated CBD-dominant oils (20–25 mg CBD, 2–3 mg THC) better than higher-THC preparations. Improvements in sleep and appetite were most noticeable when doses were given in the evening. 

The MHRA and Health Canada (2023) both highlight the “start low and go slow” principle: beginning with minimal doses and increasing gradually based on symptom response and tolerability. They also recommend consistent administration times to avoid sedation overlap with other medications. 

Safety And Clinical Oversight 

Clinicians on the GMC Specialist Register are required to review dosing schedules regularly and monitor for dizziness, gait changes, and excessive drowsiness. The MHRA’s pharmacovigilance framework also advises recording any falls or postural instability during titration, especially in frail adults. 

Clinical Bottom Line 

  • No official NHS dosing guidelines exist for cannabis in dementia. 
  • Specialists follow “start low, go slow” principles to minimise side effects. 
  • CBD-dominant products appear better tolerated than THC-rich ones. 
  • Evening dosing may improve sleep but increases sedation risk. 
  • Close monitoring and gradual adjustments are essential for safety. 

Role Of AlleviMed 

Educational organisations like AlleviMed provide clear, factual information about UK medical cannabis frameworks and responsible prescribing. They help families understand eligibility criteria and the importance of clinician-led dosing supervision but do not recommend specific products or doses. 

Takeaway 

There are no shared national dosing schedules for cannabis in dementia care, but most specialists agree on a cautious, gradual approach. Lower, CBD-rich doses and consistent timing under medical supervision help reduce risks of dizziness, confusion, and sedation. Anyone considering cannabis-based therapy for dementia should seek guidance from a qualified specialist and avoid unsupervised dosing routines. 

Julia Sutton, MSc
Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy. 

Dr. Clarissa Morton, PharmD
Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy. 

Categories